Ascaso Gimilio, Juan FranciscoCiveira, FernandoGuijarro, CarlosLópez Miranda, JoséMasana, LuísMostaza, José MaríaPedro-Botet, Juan CarlosPintó Sala, XavierValdivielso, Pedro2019-11-262019-11-262019Ascaso JF, Civeira F, Guijarro C, López Miranda J, Masana L, Mostaza JM. Et al. Indicaciones de los inhibidores de PCSK9 en la práctica clínica. Recomendaciones de la Sociedad Española de Arteriosclerosis (SEA), 2019. Clin Investig Arterioscler. 2019 May - Jun;31(3):128-139. DOI 10.1016/j.arteri.2019.04.0020214-9168http://hdl.handle.net/10230/42973A group of experts convened by the Spanish Society of Arteriosclerosis (SEA) has been in charge of updating the SEA document on the indications of PCSK9 inhibitors (PCSK9i) in clinical practice that was published in 2016. This update is justified by the fact that the data from clinical trials carried out on a large scale with PCSK9i have shown that in addition to their high potency to lower atherogenic cholesterol, they reduce the risk of atherosclerotic cardiovascular disease, both in patients with stable disease, and with recent disease, and with a high degree of security. This update provides the recommendations and level of evidence for the prescription of iPCSK9 in patients with homozygous and heterozygous familial hypercholesterolemia, with atherosclerotic cardiovascular disease, and in primary prevention in patients with very high cardiovascular risk. These recommendations have been established taking into account the concentration of LDL-C, the clinical situation of the patient, the additional risk factors and the cost-effectiveness of their use.application/pdfspa0214- 9168/ © 2019 Los Autores. Publicado por Elsevier España,S.L.U. en nombre de Sociedad Española de Arteriosclerosis. Este es un artículo Open Access bajo la licencia CCBY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/). https://doi.org/10.1016/j.arteri.2019.04.002info:eu-repo/semantics/articlehttp://dx.doi.org/10.1016/j.arteri.2019.04.002Cardiovascular diseaseClinical indicationsColesterolConsensus documentDocumento de consensoEnfermedad cardiovascularFamilial hypercholesterolemiaHipercolesterolemia familiarIndicaciones clínicasInhibidores de la proproteína convertasa subtilisina kexina 9Lipoproteínas de baja densidadLow density lipoproteinNumber needed to treatNúmero necesario a tratarProprotein convertase subtilisin kexin 9 inhibitorsTratamientoTreatmentinfo:eu-repo/semantics/openAccess